Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

614.P1.39 Acute Lymphocytic Leukemia - Therapy, Excluding Transplantation Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
CD20 up-Regulation in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia during Induction Treatment Translates into Higher Rituximab-Sensitivity

Andishe Attarbaschi1*, Angela Schumich2*, Georg Mann1*, Oskar A. Haas1, Helmut Gadner1* and Michael Dworzak2*

1St. Anna Children's Hospital, Vienna, Austria
2Children's Cancer Research Institute, Vienna, Austria

An Assay to Predict L-Asparaginase Neutralization and Enzyme Loaded Red Blood Cells to Maintain in Vivo Efficacy

Emmanuelle Dufour1*, Christine Saban-Vianey2*, Henri Coquelin3* and Yann Godfrin1*

1ERYtech Pharma, Lyon, France
2Groupement Hospitalier Est, Service maladies Héréditaires du Métabolisme et Dépistage Néonatal, Bron, France
3Service de Biologie, Hôpital St-Luc St-Joseph, Lyon, France

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003

Ajay Vora1, Rachel Wade2*, Christopher D Mitchell3*, Nicholas Goulden4* and Sue Richards2*

1Sheffield Children's Hospital, Sheffield, United Kingdom
2CTSU, Oxford
3John Radcliffe Hospital, Oxford
4GOSH, London

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003

Ajay Vora1, Rachel Wade2*, Christopher Mitchell3*, Nicholas Goulden4* and Sue Richards2*

1Sheffield Children' Hospital, Sheffield, United Kingdom
2CTSU, Oxford
3John Radcliffe Hospital, Oxford
4GOSH, London

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003

Ajay Vora1, Rachel Wade2*, Christopher Mitchell3*, Nicholas Goulden4* and Sue Richards2*

1Sheffield Children's Hospital, Sheffield, United Kingdom
2CTSU, Oxford
3John Radcliffe Hospital, Oxford
4GOSH, London

Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031

Kirk R. Schultz, MD1, William Paul Bowman2*, William Slayton, MD3, Alexander Aledo, MD4*, Meenakshi Devidas, PhD5*, Harland Sather, PhD6*, Michael J. Borowitz, MD, PhD7, Stella M. Davies, MBBS, PhD8, Michael Trigg, MD9, Bernice Pasut, RN10*, Dean Jorstad, RPh11*, Tammie Eslinger, CCRP12*, Laura Burden, CCRP13*, Chenguang Wang, MS14*, Robert Rutledge, MD15*, Bruce Camitta, MD16, Paul S. Gaynon, MD17, Andrew J. Carroll, PhD18, Nyla A. Heerema, PhD19, Naomi Winick, MD20, Stephen P. Hunger, MD21 and William L. Carroll, MD22

1B.C. Children's Hospital, Vancouver, BC, Canada
2Hematology-Oncology, Cook Childrens Medical Center, Fort Worth, TX
3College of Medicine, University of Florida, Gainesville, FL
4Weill Medical College of Cornell University, New York, NY
5Department of Epidemiology & Health Policy Research, University of Florida College of Medicine, Gainesville, FL
6Children's Oncology Group, Arcadia, CA
7Johns Hopkins University, Baltimore, MD
8Medical Ctr., Cincinnati Children's Hosp. and, Cincinnati, OH
9Thomas Jefferson University, North Wales, PA
10The Children's Hospital and the Univerisity of Colorado Cancer Center, Aurora, CO
11Midwest Children's Cancer Center, Milwaukee, WI
12Mountain States Tumor Institute, Boise, ID
13Children's Oncology Group Coordinating Center, Arcadia, CA
14Children's Oncology Group Statistics & Data Center, and the University of Florida, Gainesville, FL
15Nova Scotia Cancer Centre and Dalhousie University, Halifax, NS, Canada
16Medical College of Wisc., Milwaukee, WI
17Out-Patient Towers, Childrens Hosp. of Los Angeles, Los Angeles, CA
18Department of Genetics, University of Alabama at Birmingham, Birmingham, AL
19Ohio State University, Columbus, OH
20University of Texas Southwestern Medical Center, Dallas, TX
21University of Colorado Denver School of Medicine and The Children's Hospital, Aurora, CO
22New York University Cancer Institute, New York, NY

A Randomized Trial Investigating an Exercise Program to Prevent Osteoporosis and Motor Problems during Treatment for Childhood Acute Lymphoblastic Leukemia

Mariel L. te Winkel, MD1*, Annelies Hartman, MSc2*, Robert D. van Beek, MD1*, Sabine M.P.F. de Muinck Keizer-Schrama, Md, PhD3*, Han C.G. Kemper, PhD4*, Wim C.J. Hop, PhD5*, Marry M. van den Heuvel-Eibrink, MD, PhD1* and Rob Pieters, MD, PhD, Prof1

1Department of Pediatric Oncology / Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
2Department of Pediatric Physiotherapy, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
3Department of Pediatric Endocrinology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
4EMGO Institute, VU Medical Center, Amsterdam, Netherlands
5Epidemiology and Biostatistics, Erasmus MC, Rotterdam, Netherlands

Successful Reduction of Cranial Irradiation in Children with B Cell Precursor Acute Lymphoblastic Leukemia(ALL) through Four Consecutive ALL Studies: Long-Term Follow-up of ALL in Tokyo Children’s Cancer Study Group (TCCSG) L89-12, 92-13, 95-14 and 99-15 Studies

Chitose Ogawa1, Akira Ohara, MD2, Atsushi Manabe, MD, PhD2, Akira Kikuchi, MD.PhD2*, Katsuyoshi Koh2*, Daisuke Tomizawa2, Junya Fujimura2*, Hiroyasu Inoue2*, Syosuke Sunami2*, Eizaburo Ishii2*, Masaaki Shiohara2*, Tetsuya Mori2*, Hiroyuki Takahashi2*, Yasuhide Hayashi2*, Ryoji Hanada3* and Masahiro Tsuchida2*

1Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
2Tokyo Children's Cancer Study Group, Japan
3Division of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan

Significance of Initial Lumbar Puncture on Day8 of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia: The Results from the Tokyo Children's Cancer Study Group L99-15 Protocol

Daisuke Hasegawa1*, Atsushi Manabe1, Akira Ohara, MD2, Katsuyoshi Koh, MD.PhD3*, Chitose Ogawa1, Ryoji Hanada4* and Masahiro Tsuchida5*

1Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan
2Dept. of Pediatrics, Toho University, Tokyo, Japan
3Pediatrics, University of Tokyo, Tokyo, Japan
4Department of Hematology-Oncology, Saitama Children's Medical Center, Saitama, Japan
5Department of Pediatrics, Ibaraki Children's Hospital, Mito, Japan

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation

Adriana Balduzzi, MD1, Maria Grazia Valsecchi, PhD2*, André Schrauder, MD3*, Daniela Silvestri, MSc2*, Barbara Buldini, MD4*, Arend von Stackelberg, MD5*, Anna Maria Testi, MD6*, Thomas Klingebiel, MD7, Christina Peters, MD8*, Carmelo Rizzari, MD1*, Elena Barisone, MD9* and Martin Schrappe, MD3

1Clinica Pediatrica, Ospedale San Gerardo, Monza, Italy
2Dept of Clinical and Preventive Medicine, Università Milano Bicocca, Monza, Italy
3Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
4Pediatrics, University of Padua, Padua, Italy
5Ped. Oncology/Hematology, Charité, Med. Univ., Berlin, Berlin, Germany
6La Sapienza University, Rome, Italy
7Pediatric Hematology and Oncology, Goethe-University of Frankfurt, Germany
8St. Anna Children's Hospital, Vienna, Austria
9Pediatric Hematology Oncology, O.I.R.M. Torino, Torino, Italy

Therapy Outcome in Childhood ALL: Experience from a Tertiary Care Centre in North India

Ram Kumar Marwaha*, Ketan Kulkarni*, Amita Trehan* and Deepak Bansal*

Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children’s Oncology Group (COG)

David Robert Freyer, DO1*, Nita L. Seibel, MD2, Mei K La, MS3*, Meenakshi Devidas, PhD3*, William L. Carroll, MD1*, Stephen P. Hunger, MD1* and Paul S. Gaynon, MD4*

1Children's Oncology Group (COG), Arcadia, CA
2Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD
3Children's Oncology Group, Arcadia, CA
4Childrens's Oncology Group (COG), Arcadia, CA

A Randomised Phase II Study of Pegylated Liposomal Doxorubicine in Elderly Patients with Acute Lymphoblastic Leukemia (ALL): The GRAALL-SA1 Study

Mathilde hunault-Berger, MD, PhD1*, Thibaut Leguay2*, Xavier Thomas3, Ollivier Legrand4*, Francoise Huguet5*, Francis Witz6*, Martine Escoffre-Barbe, MD7*, Laurence Legros8*, Pascal Turlure9*, Patrice Chevallier, MD10*, Fabrice Larosa11*, jean-Yves Cahn12*, Oumedaly Reman13*, Philippe Rousselot, MD, PhD14*, Andre Delannoy, MD15, Nathalie Dhedin16*, Marina Pochitaloff17*, marie-Christine Béné18*, Norbert Ifrah, MD19 and Hervé Dombret20

1Maladies du sang, CHU, Angers, France
2CH Bordeaux
3GRAALL Group, Lyon, France
4Hopital Hotel-Dieu, Paris, France
5CHU de Toulouse, Toulouse, France
6Hématologie - Médecine interne, Hôpitaux de Brabois, Nancy, France
7Hématologie clinique, Hôpital Pontchaillou, Rennes, France
8CHU de Nice, Nice, France
9Hematology, CHU de Limoges, Limoges, France
10Hematology, CHU Hotel-Dieu, Nantes, France
11Hematology, INSERM UMR645 - CHU Jean Minjoz, Besancon
12Hématologie, Grenoble, France
13CHU Caen, Caen, France
14Hôpital Mignot and CIC9504, Versaille, France
15Hopital de Jolimont, Haine Saint Paul, Belgium
16Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France
17Cytogenetic, Marseille, France
18Immunology, Nancy, France
19Service des Maladies du Sang, CHU d'Angers, Angers, France
20Hopital Saint Louis AP-HP, Paris, France

*signifies non-member of ASH